1 |
Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol 2001;248(Suppl 1):3-10
DOI
ScienceOn
|
2 |
Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain 2002;18(6 Suppl):S119-124
DOI
|
3 |
Simpson LL. Identification of the characteristics that underlie botulinum toxin potency: implications for designing novel drugs. Biochimie 2000;82:943-953
DOI
ScienceOn
|
4 |
Ivanhoe CB, Lai JM, Francisco GE. Bruxism after brain injury: successful treatment with botulinum toxin-A. Arch Phys Med Rehabil 1997;78:1272-1273
DOI
ScienceOn
|
5 |
Van Zandijcke M, Marchau MM. Treatment of bruxism with botulinum toxin injections. J Neurol Neurosurg Psychiatry 1990;53:530
|
6 |
Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 1999;53:2102-2107
DOI
ScienceOn
|
7 |
Chauncey HH, Muench ME, Kapur KK, Wayler AH. The effect of the loss of teeth on diet and nutrition. Int Dent J 1984;34:98-104
|
8 |
Choe SW, Cho WI, Lee CK, Seo SJ. Effects of botulinum toxin type A on contouring of the lower face. Dermatol Surg 2005;31:502-507
DOI
ScienceOn
|
9 |
Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc 2000;131:211-216
DOI
|
10 |
Rosenberg D, Kaplan S, Senie R, Badner V. Relationships among dental functional status, clinical dental measures, and generic health measures. J Dent Educ 1988;52:653-657
|
11 |
Ohrbach R, List T. Psychometric properties of the jaw functional limitation scale. J Dent Res 2002;81 Special Issue A, 1023
|
12 |
Carlsson GE. Masticatory efficiency: the effect of age, the loss of teeth and prosthetic rehabilitation. Int Dent J 1984;34:93-97
|
13 |
Zhang Y, Chung SC, Chung JW. Evaluation of jaw functional limitation in TMD Patients using a Korean version of Jaw Functional Limitation Scale (JFLS). Korean J of Oral Med 2004;29:297-304
|
14 |
List T, Paulin G, Lundstrom I, Ohrbach R. Orofacial disorder diagnoses: Relationship to the jaw functional limitation scale. J Dent Res 2002;81 Special Issue A, 1024
|
15 |
Fasano A, Bentivoglio AR, Ialongo T, Soleti F, Evoli A. Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia. Neurology 2005;64:2155-2156
DOI
|
16 |
Mandel L, Tharakan M. Treatment of unilateral masseteric hypertrophy with botulinum toxin: case report. J Oral Maxillofac Surg 1999;57:1017-1019
DOI
|
17 |
Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 1989;98:93-97
|
18 |
Arikan OK, Tan FU, Kendi T, Koc C. Use of botulinum toxin type a for the treatment of masseteric muscle hypertrophy. J Otolaryngol 2006;35:40-43
DOI
ScienceOn
|
19 |
Balash Y, Giladi N. Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol 2004;11:361-370
DOI
ScienceOn
|
20 |
Stegenga B, de Bont LG, de Leeuw R, Boering G. Assessment of mandibular function impairment associated with temporomandibular joint osteoarthrosis and internal derangement. J Orofac Pain 1993;7:183-195
|
21 |
Lew MF. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain 2002;18(6 Suppl):S142-146
DOI
|
22 |
Dressler D, Saberi FA. Botulinum toxin: mechanisms of action. Eur Neurol 2005;53:3-9
|
23 |
Pidcock FS, Wise JM, Christensen JR. Treatment of severe post-traumatic bruxism with botulinum toxin-A: case report. J Oral Maxillofac Surg 2002;60:115-117
DOI
ScienceOn
|
24 |
Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 25;324:1186-1194
|